Insider Trading Alert - SSB, IMMU And ADI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 9, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $352.00 to $81,483,250.00.

Highlighted Stocks Traded by Insiders:

South State (SSB) - FREE Research Report

Hill Robert R Jr, who is Chief Executive Officer at South State, sold 2,092 shares at $73.00 on June 9, 2015. Following this transaction, the Chief Executive Officer owned 135,363 shares meaning that the stake was reduced by 1.52% with the 2,092-share transaction.

The shares most recently traded at $75.30, up $2.30, or 3.05% since the insider transaction. Historical insider transactions for South State go as follows:

  • 4-Week # shares bought: 310
  • 4-Week # shares sold: 6,900
  • 12-Week # shares bought: 310
  • 12-Week # shares sold: 6,900
  • 24-Week # shares bought: 1,310
  • 24-Week # shares sold: 7,250

The average volume for South State has been 77,400 shares per day over the past 30 days. South State has a market cap of $1.8 billion and is part of the financial sector and banking industry. Shares are up 9.56% year-to-date as of the close of trading on Tuesday.

South State Corporation operates as the bank holding company for South State Bank that provides a range of retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans. The stock currently has a dividend yield of 1.31%. The company has a P/E ratio of 21.4. Currently, there are 4 analysts who rate South State a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SSB - FREE

TheStreet Quant Ratings rates South State as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full South State Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Immunomedics (IMMU) - FREE Research Report

Stark Don C, who is Director at Immunomedics, sold 5,732 shares at $4.14 on June 9, 2015. Following this transaction, the Director owned 30,450 shares meaning that the stake was reduced by 15.84% with the 5,732-share transaction.

The shares most recently traded at $4.62, up $0.48, or 10.35% since the insider transaction. Historical insider transactions for Immunomedics go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 10,000

The average volume for Immunomedics has been 914,500 shares per day over the past 30 days. Immunomedics has a market cap of $470.1 million and is part of the health care sector and drugs industry. Shares are up 4.79% year-to-date as of the close of trading on Tuesday.

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Currently, there are 3 analysts who rate Immunomedics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IMMU - FREE

TheStreet Quant Ratings rates Immunomedics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Immunomedics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Analog Devices (ADI) - FREE Research Report

Roche Vincent, who is President & CEO at Analog Devices, sold 16,623 shares at $66.23 on June 9, 2015. Following this transaction, the President & CEO owned 7,791 shares meaning that the stake was reduced by 68.09% with the 16,623-share transaction.

The shares most recently traded at $67.61, up $1.38, or 2.03% since the insider transaction. Historical insider transactions for Analog Devices go as follows:

  • 4-Week # shares sold: 500
  • 12-Week # shares sold: 64,750
  • 24-Week # shares sold: 141,250

The average volume for Analog Devices has been 2.5 million shares per day over the past 30 days. Analog Devices has a market cap of $20.7 billion and is part of the technology sector and electronics industry. Shares are up 18.32% year-to-date as of the close of trading on Tuesday.

Analog Devices, Inc. engages in the design, manufacture, and marketing of analog, mixed-signal, and digital signal processing integrated circuits (ICs) for use in industrial, automotive, consumer, and communication markets worldwide. The stock currently has a dividend yield of 2.43%. The company has a P/E ratio of 31.1. Currently, there are 12 analysts who rate Analog Devices a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADI - FREE

TheStreet Quant Ratings rates Analog Devices as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Analog Devices Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research

If you liked this article you might like

Mid-Cap Bank M&A Could Surge as GOP Looks to Overhaul Financial Regulations

Mid-Cap Bank M&A Could Surge as GOP Looks to Overhaul Financial Regulations

Insider Trading Alert - FELE, NUAN And SSB Traded By Insiders

Insider Trading Alert - FELE, NUAN And SSB Traded By Insiders

6 Small Banks That Could Be Acquisition Targets -- and 3 Potential Buyers

6 Small Banks That Could Be Acquisition Targets -- and 3 Potential Buyers

Why FCB and Other Midcap Banks Could Go Into Play

Why FCB and Other Midcap Banks Could Go Into Play

Insider Trading Alert - IEC, SSB And SBH Traded By Insiders

Insider Trading Alert - IEC, SSB And SBH Traded By Insiders